Document Detail


Sustained release nitric oxide from long-lived circulating nanoparticles.
MedLine Citation:
PMID:  20460149     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The current limitations of nitric oxide (NO) delivery systems have stimulated an extraordinary interest in the development of compounds that generate NO in a controlled and sustained manner with a heavy emphasis on the treatment of cardiovascular disease states. This work describes the positive physiological response to the infusion of NO-releasing nanoparticles prepared using a new platform based on hydrogel/glass hybrid nanoparticles. When exposed to moisture, these nanoparticles slowly release therapeutic levels of NO, previously generated through thermal reduction of nitrite to NO trapped within the dry particles. The controlled and sustained release of NO observed from these nanoparticles (NO-np) is regulated by its hydration over extended periods of time. In a dose-dependent manner, circulating NO-np both decreased mean arterial blood pressure and increased exhaled concentrations of NO over a period of several hours. Circulating NO-np induced vasodilatation and increased microvascular perfusion during their several hour circulation lifetime. Control nanoparticles (control-np; without nitrite) did not induce changes in arterial pressure, although a decrease in the number of capillaries perfused and an increase in leukocyte rolling and immobilization in the microcirculation were observed. The NO released by the NO-np prevents the inflammatory response observed after infusion of control-np. These data suggest that NO release from NO-np is advantageous relative to other NO-releasing compounds, because it does not depend on chemical decomposition or enzymatic catalysis; it is only determined by the rate of hydration. Based on the observed physiological properties, NO-np has clear potential as a therapeutic agent and as a research tool to increase our understanding of NO signaling mechanisms within the vasculature.
Authors:
Pedro Cabrales; George Han; Camille Roche; Parimala Nacharaju; Adam J Friedman; Joel M Friedman
Related Documents :
17064669 - No-cgmp pathway at ventrolateral medullary cardiac inhibitory sites enhances the barore...
8794819 - Roles of prostaglandins and nitric oxide in the effect of endothelin-1 on renal hemodyn...
2160309 - Early myocardial dysfunction induced with endotoxin in rhesus monkeys.
8605799 - Analysis of responses to pentoxifylline in the pulmonary vascular bed of the cat.
9023509 - Effects of nitric oxide on diaphragmatic muscle endurance and strength in pigs.
8623789 - Nitric oxide is involved in flow-induced dilation of isolated human small fetoplacental...
9407569 - Frequency responses of infant air-balloon versus liquid-filled catheters for intra-esop...
23173589 - Device-based therapies for resistant hypertension.
8119459 - Systemic and uterine vascular response to serotonin in third trimester pregnant ewes.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-05-09
Journal Detail:
Title:  Free radical biology & medicine     Volume:  49     ISSN:  1873-4596     ISO Abbreviation:  Free Radic. Biol. Med.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-13     Completed Date:  2011-01-21     Revised Date:  2014-06-02    
Medline Journal Info:
Nlm Unique ID:  8709159     Medline TA:  Free Radic Biol Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  530-8     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cricetinae
Delayed-Action Preparations
Drug Delivery Systems*
Hydrogel / chemistry
Hydrogen-Ion Concentration
Male
Nanoparticles / chemistry*
Nanotechnology / instrumentation,  methods
Nitric Oxide / administration & dosage*,  chemistry*,  metabolism,  pharmacokinetics
Particle Size
Signal Transduction
Grant Support
ID/Acronym/Agency:
P01 HL071064/HL/NHLBI NIH HHS; P01 HL071064/HL/NHLBI NIH HHS; P01 HL071064-05/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 25852-47-5/Hydrogel; 31C4KY9ESH/Nitric Oxide
Comments/Corrections
Comment In:
Free Radic Biol Med. 2010 Aug 15;49(4):528-9   [PMID:  20639121 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro Neurotoxicity of Magnetic Resonance Imaging (MRI) Contrast Agents: Influence of the molecul...
Next Document:  Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannab...